Warning
This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.

3-MeO-PCP: Difference between revisions

From PsychonautWiki Archive
Jump to navigation Jump to search
← Older editNewer edit →
>Unintended
As I can tell, "spinal column" refers to the backbone. "Spinal cord" would be the correct term for the CNS component...
>Unity
Grammatics and effects cleanup/reorganization
Line 11: Line 11:


==Chemistry==
==Chemistry==
3-MeO-PCP, or 3-Methoxyphencyclidine, is a synthetic dissociative of the arylcyclohexylamine class. 3-MeO-PCP contains cyclohexane, a six-member saturated ring, bonded to two additional rings at R<sub>1</sub>. One of these rings is a piperidine ring, a nitrogenous six member ring, bonded at its nitrogen group. The other ring is an aromatic phenyl ring, substituted at R<sub>3</sub> with a methoxy group.  
3-Methoxyphencyclidine, or 3-MeO-PCP, is a synthetic dissociative of the arylcyclohexylamine class. 3-MeO-PCP contains cyclohexane, a six-member saturated ring, bonded to two additional rings at R<sub>1</sub>. One of these rings is a piperidine ring, a nitrogenous six member ring, bonded at its nitrogen group. The other ring is an aromatic phenyl ring, substituted at R<sub>3</sub> with a methoxy group.  


3-MeO-PCP is a [[PCP]] derivative and structurally analogous to [[4-MeO-PCP]].
3-MeO-PCP is a [[PCP]] derivative and structurally analogous to [[4-MeO-PCP]].
Line 17: Line 17:
==Pharmacology==
==Pharmacology==
{{Further|NMDA receptor antagonist}}
{{Further|NMDA receptor antagonist}}
3-MeO-PCP acts as an [[NMDA receptor antagonist]]. A specific subtype of glutamate receptor, NMDA (N-Methyl-D-Aspartate), modulates the transmission of electrical signals between neurons in the brain and spinal cord; for the signals to pass, the receptor must be open. Dissociatives inhibit the normal functioning NMDA receptors by binding to and blocking them. This disruption of neural network activity leads to loss of normal cognitive and affective processing, psychomotor functioning, anesthesia and eventually an almost identical equivalent of the famous “[http://en.wikipedia.org/wiki/K-hole k-hole].”
3-MeO-PCP acts as an [[NMDA receptor antagonist]]. A specific subtype of glutamate receptor, NMDA (N-Methyl-D-Aspartate), modulates the transmission of electrical signals between neurons in the brain and spinal cord; for the signals to pass, the receptor must be open.  
 
Dissociatives inhibit the normal functioning NMDA receptors by binding to and blocking them. This disruption of neural network activity leads to loss of normal cognitive and affective processing, psychomotor functioning, anesthesia and eventually an almost identical equivalent of the famous “[http://en.wikipedia.org/wiki/K-hole k-hole].”


3-MeO-PCP has a Ki of 20 nM for the NMDA receptor, 216 nM for the serotonin transporter (SERT) and 42 nM for the sigma-1 receptor.<ref name=&quot;AMCD&quot;>Advisory Council on the Misuse of Drugs (ACMD) Methoxetamine report, 2012 | https://www.gov.uk/government/publications/advisory-council-on-the-misuse-of-drugs-acmd-methoxetamine-report-2012</ref> It binds to the NMDA receptor with higher affinity than PCP and has the highest affinity of the three isomeric anisyl-substitutions, followed by 2-MeO-PCP and 4-MeO-PCP.  
3-MeO-PCP has a Ki of 20 nM for the NMDA receptor, 216 nM for the serotonin transporter (SERT) and 42 nM for the sigma-1 receptor.<ref name=&quot;AMCD&quot;>Advisory Council on the Misuse of Drugs (ACMD) Methoxetamine report, 2012 | https://www.gov.uk/government/publications/advisory-council-on-the-misuse-of-drugs-acmd-methoxetamine-report-2012</ref> It binds to the NMDA receptor with higher affinity than PCP and has the highest affinity of the three isomeric anisyl-substitutions, followed by 2-MeO-PCP and 4-MeO-PCP.  


Although 3-MeO-PCP was once famously described as possessing opioid or dopaminergic activity (based on early phenomenological analysis),<ref name="chemist">Interview with a ketamine chemist: or to be more precise, an arylcyclohexylamine chemist | http://www.vice.com/read/interview-with-ketamine-chemist-704-v18n2</ref> this supposition is contradicted by data showing 3-MeO-PCP to be a potent and selective ligand for the NMDA receptor without appreciable affinity for the µ-opioid receptor or dopamine transporter.<ref name="AMCD2">The Ketamine Analogue Methoxetamine and 3- and 4-Methoxy Analogues of Phencyclidine Are High Affinity and Selective Ligands for the Glutamate NMDA Receptor | http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0059334</ref> 3-MeO-PCP was preceded by the less potent dissociative 4-MeO-PCP and first became available as a [[research chemical]] in 2011.<ref name="PCP2MXE" />
Although 3-MeO-PCP was once famously described as possessing opioid or dopaminergic activity,<ref name="chemist">Interview with a ketamine chemist: or to be more precise, an arylcyclohexylamine chemist | http://www.vice.com/read/interview-with-ketamine-chemist-704-v18n2</ref> this supposition is contradicted by data showing 3-MeO-PCP to be a potent and selective ligand for the NMDA receptor without appreciable affinity for the µ-opioid receptor or dopamine transporter.<ref name="AMCD2">The Ketamine Analogue Methoxetamine and 3- and 4-Methoxy Analogues of Phencyclidine Are High Affinity and Selective Ligands for the Glutamate NMDA Receptor | http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0059334</ref> 3-MeO-PCP was preceded by the less potent dissociative 4-MeO-PCP and first became available as a [[research chemical]] in 2011.<ref name="PCP2MXE" />
   
   
==Subjective effects==
==Subjective effects==
3-MeO-PCP can be said to feel considerably more stimulating and less sedating than other [[dissociative]]s such as [[ketamine]] or [[MXE]]. At lower doses, it can induce sensory enhancements such as [[color enhancement]], [[acuity enhancement]], [[tactile enhancement]], [[auditory enhancement]] and [[bodily control enhancement]]. However, at medium to high doses, it presents sensory suppressions such as [[tactile suppression]], [[motor control loss]], [[auditory suppression]] and [[acuity suppression]]. Based on a large amount of experience reports, it appears to be considerably more likely to induce [[mania]], [[delusions]], and [[psychosis]] than other dissociatives (possibly due to its unusually high potency, [[compulsive redosing|compulsivity]], [[stimulation]], and erratic dose response).
3-MeO-PCP can be said to feel considerably more stimulating and less immobilizing than other [[dissociatives]] such as [[ketamine]] or [[MXE]]. At lower doses, it can induce sensory enhancements such as [[color enhancement]], [[acuity enhancement]], [[tactile enhancement]], [[auditory enhancement]] and [[bodily control enhancement]]. However, at medium to high doses, it presents sensory suppressions such as [[tactile suppression]], [[motor control loss]], [[auditory suppression]] and [[acuity suppression]]. Based on a large amount of experience reports, it appears to be considerably more likely to induce [[mania]], [[delusions]], and [[psychosis]] than other dissociatives (possibly due to its unusually high potency, [[compulsive redosing|compulsivity]] and erratic dose response).
   
   
{{Preamble/SubjectiveEffects}}
{{Preamble/SubjectiveEffects}}
Line 33: Line 35:
*'''[[Effect::Stimulation]]''' - This substance is regarded to be noticeably stimulating in comparison to other dissociatives such as [[ketamine]], [[MXE]], or [[DCK]]. The stimulation it presents is clean and comfortable in a manner which is far closer to that of [[3-MeO-PCE]] than that of [[O-PCE]].
*'''[[Effect::Stimulation]]''' - This substance is regarded to be noticeably stimulating in comparison to other dissociatives such as [[ketamine]], [[MXE]], or [[DCK]]. The stimulation it presents is clean and comfortable in a manner which is far closer to that of [[3-MeO-PCE]] than that of [[O-PCE]].
**'''[[Effect::Perception of decreased weight]]'''
**'''[[Effect::Perception of decreased weight]]'''
*'''[[Effect::Restless legs]]'''
**'''[[Effect::Restless legs]]'''
*'''[[Effect::Spontaneous physical sensations]]''' - The body high of this compound can be described in terms of its style variations as a motionless, constant, sharp, all-encompassing, and euphoric activation of nerve endings across the body.
*'''[[Effect::Spontaneous physical sensations]]''' - The body high of this compound can be described in terms of its style variations as a motionless, constant, sharp, all-encompassing, and euphoric activation of nerve endings across the body.
*'''[[Effect::Physical euphoria]]''' - 3-MeO-PCP has been reported to more readily induce euphoria than most other dissociatives, such as [[ketamine]] or [[diphenidine]], especially of the manic variant.
**'''[[Effect::Physical euphoria]]''' - 3-MeO-PCP has been reported to more readily induce euphoria than most other dissociatives, such as [[ketamine]] or [[diphenidine]], especially of the manic variant.
*'''[[Effect::Tactile enhancement]]''' and '''[[Effect::Tactile suppression]]''' - At lower dosages, this compound tends to induce tactile enhancements. At higher dosages, this enhancement shifts towards tactile suppressions and [[pain relief|anesthesia]].
*'''[[Effect::Tactile enhancement]]''' or '''[[Effect::Tactile suppression]]''' - At lower dosages, this compound tends to induce tactile enhancements. At higher dosages, this enhancement shifts towards tactile suppressions and [[pain relief|anesthesia]].
*'''[[Effect::Pain relief]]''' - This substance produces distinct nerve-signal blocking anesthetic effects typically required in surgical settings, but only in the stronger to heavier dose ranges.
*'''[[Effect::Pain relief]]''' - This substance produces distinct nerve-signal blocking anesthetic effects typically required in surgical settings, but only in the stronger to heavier dose ranges.
*'''[[Effect::Bodily control enhancement]]''' and '''[[Motor control loss]]''' - At lower dosages this compound typically induces enhancements in bodily control. At higher dosages, this enhancement shifts towards motor control  
*'''[[Effect::Bodily control enhancement]]''' or '''[[Motor control loss]]''' - At lower dosages this compound typically induces enhancements in bodily control. At higher dosages, this enhancement shifts towards motor control  
*'''[[Effect::Changes in felt gravity]]'''
*'''[[Effect::Spatial disorientation]]''' - In contrast to other dissociatives like ketamine, this effect is only prominent at high doses.  
*'''[[Effect::Spatial disorientation]]''' - In contrast to other dissociatives like ketamine, this effect is only prominent at high doses.  
*'''[[Effect::Appetite suppression]]'''
*'''[[Effect::Appetite suppression]]'''
Line 45: Line 46:
*'''[[Effect::Respiratory depression]]''' - This effect can be present at heavier dosage levels.{{citation needed}}
*'''[[Effect::Respiratory depression]]''' - This effect can be present at heavier dosage levels.{{citation needed}}
*'''[[Effect::Physical autonomy]]'''
*'''[[Effect::Physical autonomy]]'''
*'''[[Effect::Olfactory hallucinations]]
*'''[[Effect::Olfactory hallucinations]]'''
*'''[[Effect::Optical sliding]]'''
*'''[[Effect::Optical sliding]]'''
*'''[[Effect::Abnormal heartbeat]]'''
*'''[[Effect::Abnormal heartbeat]]'''
Line 54: Line 55:
*'''[[Effect::Dizziness]]'''
*'''[[Effect::Dizziness]]'''
*'''[[Effect::Difficulty urinating]]'''
*'''[[Effect::Difficulty urinating]]'''
*'''[[Effect::Seizure]]''' - This extent to which this effect can be produced is unknown but can likely happen in those predisposed to them, especially while in physically taxing conditions such as being dehydrated, fatigued or undernourished.
*'''[[Effect::Seizure]]''' - The extent to which this effect can be produced is unknown but can likely happen in those predisposed to them, especially while in physically taxing conditions such as being dehydrated, fatigued or undernourished.


}}
}}
{{effects/disconnective|
{{effects/disconnective|
*'''[[Effect::Tactile disconnection]]'''
*'''[[Effect::Tactile disconnection]]'''
*'''[[Effect::Visual disconnection]]''' - This eventually results in 3-MeO-PCP's equivalent of the notorious "[https://en.wikipedia.org/wiki/K-hole k-hole]" or, more specifically, ''[[Visual disconnection#Holes, spaces and voids|holes, spaces and voids]]'' alongside of ''[[Visual disconnection#Structures|structures]]''.
*'''[[Effect::Visual disconnection]]''' - This eventually results in 3-MeO-PCP's equivalent of the "[https://en.wikipedia.org/wiki/K-hole k-hole]" or, more specifically, ''[[Visual disconnection#Holes, spaces and voids|holes, spaces and voids]]'' alongside of ''[[Visual disconnection#Structures|structures]]''.
*'''[[Effect::Consciousness disconnection]]'''
*'''[[Effect::Consciousness disconnection]]'''


Line 65: Line 66:
{{effects/auditory|
{{effects/auditory|


*'''[[Effect::Auditory enhancement|Enhancement]]''' - This effect is reported to only occur at lower doses.
*'''[[Effect::Auditory enhancement]]''' - This effect is reported to only occur at lower doses.
*'''[[Effect::Auditory suppression|Suppression]]'''  
*'''[[Effect::Auditory suppression]]'''  
*'''[[Effect::Auditory distortion|Distortions]]'''
*'''[[Effect::Auditory distortion]]'''
*'''[[Effect::Auditory hallucinations|Hallucinations]]'''
*'''[[Effect::Auditory hallucinations]]'''


}}
}}
Line 79: Line 80:


*'''[[Effect::Anxiety suppression]]'''
*'''[[Effect::Anxiety suppression]]'''
*'''[[Effect::Consciousness disconnection]]'''
*'''[[Effect::Disinhibition]]'''
*'''[[Effect::Cognitive euphoria]]'''
*'''[[Effect::Compulsive redosing]]''' - This effect is more prominent based on the route of administration used. For example, it is especially present when smoked or vaporized, due to the relative abruptness of the substance entering and leaving the bloodstream.
*'''[[Effect::Compulsive redosing]]''' - This effect is more prominent based on the route of administration used. For example, it is especially present when smoked or vaporized, due to the relative abruptness of the substance entering and leaving the bloodstream.
*'''[[Effect::Conceptual thinking]]'''
*'''[[Effect::Conceptual thinking]]'''
*'''[[Effect::Creativity enhancement]]'''
*'''[[Effect::Creativity enhancement]]'''
*'''[[Effect::Déjà vu]]'''
*'''[[Effect::Déjà vu]]'''
*'''[[Effect::Mania]]''' - This effect is reportedly more common on 3-MeO-PCP than most other dissociatives. It typically occurs during the offset of the trip, but can also occur during the onset and come up as well.
*'''[[Effect::Mania]]''' - This effect is reportedly more common on 3-MeO-PCP than most other dissociatives. It typically occurs during the offset of the experience, but can also occur during the onset and come up as well.
*'''[[Effect::Depersonalization]]'''
*'''[[Effect::Depersonalization]]''' & '''[[Effect::Derealization]]'''
*'''[[Effect::Derealization]]'''
*'''[[Effect::Psychosis]]''' - This effect has been reported to be more common on 3-MeO-PCP than most other dissociatives, such as [[MXE]] or [[ketamine]]. It typically occurs during the [[offset]] of the experience, but can also occur during the [[onset]] and come up as well.
*'''[[Effect::Disinhibition]]'''
*'''[[Effect::Psychosis]]''' - This effect has been reported to be more common on 3-MeO-PCP than most other dissociatives, such as [[MXE]] or [[Ketamine]]. It typically occurs during the [[offset]] of the trip, but can also occur during the [[onset]] and come up as well.
*'''[[Effect::Delusions]]''' - Like psychosis, this effect is reportedly more common on 3-MeO-PCP than most other dissociatives.
*'''[[Effect::Delusions]]''' - Like psychosis, this effect is reportedly more common on 3-MeO-PCP than most other dissociatives.
*'''[[Effect::Dream potentiation]]'''
*'''[[Effect::Dream potentiation]]'''
*'''[[Effect::Cognitive euphoria]]'''
*'''[[Effect::Memory suppression]]'''  
*'''[[Effect::Memory suppression]]'''  
**'''[[Effect::Ego death]]'''
**'''[[Effect::Ego death]]'''
Line 104: Line 103:
{{effects/visual|
{{effects/visual|


*'''[[Effect::Visual acuity enhancement]]''' - This effect has been reported as being especially present at low dosages.
*'''[[Effect::Visual acuity enhancement]]''' or '''[[Effect::Visual acuity suppression]]''' - While lower doses of this compound tend to produce mild visual acuity enhancements, this effect quickly disappears as one's general visual faculties become suppressed as the dose is increased.
*'''[[Effect::Visual acuity suppression]]''' - While lower doses of this compound tend to produce mild visual acuity enhancements, this effect quickly disappears as one's general visual faculties become suppressed as the dose is increase.
*'''[[Effect::Double vision]]'''
*'''[[Effect::Double vision]]'''
*'''[[Effect::Frame rate suppression]]'''
*'''[[Effect::Frame rate suppression]]'''
Line 111: Line 109:


====Distortions====
====Distortions====
*'''[[Effect::Environmental cubism]]'''
*'''[[Effect::Perspective distortions]]'''
*'''[[Effect::Perspective distortions]]'''
*'''[[Effect::Scenery slicing]]'''
*'''[[Effect::Scenery slicing]]'''


====Hallucinatory states====
====Hallucinatory states====
*'''[[Effect::Internal hallucinations]]''' (''[[effect::autonomous entities]]''; ''[[effect::settings, sceneries, and landscapes]]''; ''[[effect::alterations in perspective]]'' and ''[[effect::scenarios and plots]]'')
*'''[[Effect::Internal hallucinations]]''' (''[[effect::settings, sceneries, and landscapes]]''; ''[[effect::alterations in perspective]]'' and ''[[effect::scenarios and plots]]'')


}}
}}
}}
}}
===Experience reports===
===Experience reports===
Anecdotal reports which describe the effects of this compound within our [[experience index]] include:
Anecdotal reports which describe the effects of this compound within our [[experience index]] include:
Line 131: Line 127:
The toxicity and long-term health effects of recreational 3-MeO-PCP use has not been studied in any scientific context and the exact [[Toxicity::toxic dosage is unknown]]. This is because 3-MeO-PCP has very short history of human usage.  
The toxicity and long-term health effects of recreational 3-MeO-PCP use has not been studied in any scientific context and the exact [[Toxicity::toxic dosage is unknown]]. This is because 3-MeO-PCP has very short history of human usage.  


There is one death involving this drug in the medical literature. In this case, the invidual's cause of death was determined to be from a combination of 3-MeO-PCP, [[amphetamine]], and [[diphenhydramine]].<ref>Bakota, E., Arndt, C., Romoser, A. A., & Wilson, S. K. (2016). Fatal Intoxication Involving 3-MeO-PCP: A Case Report and Validated Method. Journal of Analytical Toxicology, 40(7), 504–510. http://doi.org/10.1093/jat/bkw056</ref>
There is one death involving this substance recorded in the medical literature. In this case, the invidual's cause of death was determined to be from a combination of 3-MeO-PCP, [[amphetamine]], and [[diphenhydramine]].<ref>Bakota, E., Arndt, C., Romoser, A. A., & Wilson, S. K. (2016). Fatal Intoxication Involving 3-MeO-PCP: A Case Report and Validated Method. Journal of Analytical Toxicology, 40(7), 504–510. http://doi.org/10.1093/jat/bkw056</ref>


===Tolerance and addiction potential===
===Tolerance and addiction potential===
The chronic use of 3-MeO-PCP can be considered [[Addiction potential::highly addictive with a high potential for adverse side effects such as psychosis]]. In comparison to other [[dissociative]]s, 3-MeO-PCP has been reported to be more addictive than [[MXE]], [[diphenidine]], [[ephenidine]], [[DCK]], and [[ketamine]]. When addiction has developed, cravings and [[withdrawal effects]] may occur if a person suddenly stops their usage. There have been multiple reports across the internet of people becoming seriously addicted daily users of this substance so serious precautions and considerations should be taken before trying this substance.
The chronic use of 3-MeO-PCP can be considered [[Addiction potential::highly addictive with a high potential for adverse side effects such as psychosis]]. In comparison to other [[dissociatives]], 3-MeO-PCP has been reported to be more addictive than [[MXE]], [[diphenidine]], [[ephenidine]], [[DCK]], and [[ketamine]]. When addiction has developed, cravings and [[withdrawal effects]] may occur if a person suddenly stops their usage. There have been multiple reports across the internet of people becoming seriously addicted daily users of this substance so serious precautions and considerations should be taken before trying this substance.


Tolerance to many of the effects of 3-MeO-PCP develops [[Time to full tolerance::with prolonged and repeated use]]. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about [[Time to half tolerance::3 - 7 days]] for the tolerance to be reduced to half and [[Time to zero tolerance::1 - 2 weeks]] to be back at baseline (in the absence of further consumption). 3-MeO-PCP presents cross-tolerance with [[Cross-tolerance::all [[dissociative]]s]], meaning that after the consumption of 3-MeO-PCP, all [[dissociative]]s will have a reduced effect.
Tolerance to many of the effects of 3-MeO-PCP develops [[Time to full tolerance::with prolonged and repeated use]]. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about [[Time to half tolerance::3 - 7 days]] for the tolerance to be reduced to half and [[Time to zero tolerance::1 - 2 weeks]] to be back at baseline (in the absence of further consumption). 3-MeO-PCP presents cross-tolerance with [[Cross-tolerance::all [[dissociative]]s]], meaning that after the consumption of 3-MeO-PCP, all [[dissociatives]] will have a reduced effect.


===Psychosis===
===Psychosis===
Line 150: Line 146:
Due to the risk of psychosis, it is not recommended to combine this drug with other substances, especially [[stimulant]]s, [[psychedelic]]s, or other [[dissociative]]s like [[MXE]]. [https://www.google.com/ Independent research] should always be done to ensure that a combination of two or more substances is safe before consumption.
Due to the risk of psychosis, it is not recommended to combine this drug with other substances, especially [[stimulant]]s, [[psychedelic]]s, or other [[dissociative]]s like [[MXE]]. [https://www.google.com/ Independent research] should always be done to ensure that a combination of two or more substances is safe before consumption.


It is strongly recommended that one use [[responsible drug use|harm reduction practices]], such as [[volumetric dosing]], when using this substance to ensure the administration of the intended dose.
It is strongly recommended that one use [[responsible drug use|harm reduction practices]], such as [[volumetric dosing]], when using this substance to ensure the accurate administration of the intended dose.


===Urinary tract effects===
===Urinary tract effects===
Line 162: Line 158:
*'''Incontinence''' - This is the leakage of urine.
*'''Incontinence''' - This is the leakage of urine.


All of these, however, can be avoided by refraining from using 3-MeO-PCP on a daily or even weekly basis and manually limiting one's usage of the substance.
All of these, however, can be avoided by refraining from using 3-MeO-PCP regularly (on a daily or weekly basis) and manually limiting one's usage of the substance.


===Dangerous interactions===
===Dangerous interactions===

Revision as of 19:49, 5 July 2017

3-MeO-PCP may be more likely to cause mania, delusions, and psychosis than other dissociatives.[1][2][3]

It is strongly discouraged to take this substance in high dosages, for multiple days in a row, or in combination with other substances that increase the risk of psychosis. Please see this section for more details.

Summary sheet: 3-MeO-PCP
3-MeO-PCP
Chemical Nomenclature
Common names 3-MeO-PCP, 3-MeO
Substitutive name 3-Methoxyphencyclidine
Systematic name 1-[1-(3-Methoxyphenyl)cyclohexyl]-piperidine
Class Membership
Psychoactive class Dissociative
Chemical class Arylcyclohexylamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.


⇣ Smoked
Dosage
Threshold 2 mg
Light 5 - 10 mg
Common 10 - 20 mg
Strong 20 - 25 mg
Heavy 25 mg + Heavy doses may result in psychosis and mania.[4]
Duration
Total 45 - 120 minutes
⇣ Oral
Dosage
Threshold 2 mg
Light 4 - 8 mg
Common 8 - 15 mg
Strong 15 - 25 mg
Heavy 25 mg + Heavy doses may result in psychosis and mania.[4]
Duration
Total 4 - 8 hours
Onset 30 - 90 minutes
Come up 45 - 120 minutes
Peak 2 - 3 hours
Offset 1 - 2 hours
After effects 4 - 48 hours



⇣ Insufflated
Dosage
Threshold 1 mg
Light 2 - 5 mg
Common 5 - 10 mg
Strong 10 - 15 mg
Heavy 15 mg + Heavy doses may result in psychosis and mania.[4]
Duration
Total 3 - 5 hours
Onset 5 - 30 minutes
Come up 45 - 90 minutes
Peak 1.5 - 2 hours
Offset 45 - 60 minutes
After effects 4 - 48 hours






DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

Interactions
Stimulants
Depressants

3-Methoxyphencyclidine (commonly known as 3-MeO-PCP or 3-MeO) is a synthetic dissociative substance of the arylcyclohexylamine chemical class that produces potent, highly dose-sensitive dissociative, hallucinogenic and prominent stimulating effects when administered.

The compound was first synthesized in 1979 to investigate the structure-activity relationship of phencyclidine (PCP) derivatives. The activity of 3-MeO-PCP in humans was not described until 1999 when a chemist using the pseudonym John Q. Beagle wrote that 3-MeO-PCP was qualitatively similar to PCP with comparable potency.[5]

Like other substances of its class, particularly methoxetamine (MXE), phencyclidine (PCP), and 3-MeO-PCE, it is known to primarily induce a state referred to as "dissociative anesthesia", albeit the extent to which this occurs has been reported to be highly dose-dependent and variable in its effects.[citation needed] Its most common routes of administration include oral, sublingual or nasal administration and has been noted for its subtle come up and tendency to produce delusions of sobriety, which can lead to compulsive redosing.[6]

Today, 3-MeO-PCP is rarely sold on the streets and almost exclusively obtained as a gray area research chemical through the use of online vendors[7], where it is commonly used as a recreational substance and, more rarely and controversially, as a synthetic novel entheogen.[citation needed] Due to its potent dissociative, stimulant and hallucinogenic effects, commonly reported habit-forming properties, as well as unknown toxicity profile, it is strongly recommended that one use proper harm reduction practices if choosing to use this substance.

Chemistry

3-Methoxyphencyclidine, or 3-MeO-PCP, is a synthetic dissociative of the arylcyclohexylamine class. 3-MeO-PCP contains cyclohexane, a six-member saturated ring, bonded to two additional rings at R1. One of these rings is a piperidine ring, a nitrogenous six member ring, bonded at its nitrogen group. The other ring is an aromatic phenyl ring, substituted at R3 with a methoxy group.

3-MeO-PCP is a PCP derivative and structurally analogous to 4-MeO-PCP.

Pharmacology

Further information: NMDA receptor antagonist

3-MeO-PCP acts as an NMDA receptor antagonist. A specific subtype of glutamate receptor, NMDA (N-Methyl-D-Aspartate), modulates the transmission of electrical signals between neurons in the brain and spinal cord; for the signals to pass, the receptor must be open.

Dissociatives inhibit the normal functioning NMDA receptors by binding to and blocking them. This disruption of neural network activity leads to loss of normal cognitive and affective processing, psychomotor functioning, anesthesia and eventually an almost identical equivalent of the famous “k-hole.”

3-MeO-PCP has a Ki of 20 nM for the NMDA receptor, 216 nM for the serotonin transporter (SERT) and 42 nM for the sigma-1 receptor.[8] It binds to the NMDA receptor with higher affinity than PCP and has the highest affinity of the three isomeric anisyl-substitutions, followed by 2-MeO-PCP and 4-MeO-PCP.

Although 3-MeO-PCP was once famously described as possessing opioid or dopaminergic activity,[9] this supposition is contradicted by data showing 3-MeO-PCP to be a potent and selective ligand for the NMDA receptor without appreciable affinity for the µ-opioid receptor or dopamine transporter.[10] 3-MeO-PCP was preceded by the less potent dissociative 4-MeO-PCP and first became available as a research chemical in 2011.[5]

Subjective effects

3-MeO-PCP can be said to feel considerably more stimulating and less immobilizing than other dissociatives such as ketamine or MXE. At lower doses, it can induce sensory enhancements such as color enhancement, acuity enhancement, tactile enhancement, auditory enhancement and bodily control enhancement. However, at medium to high doses, it presents sensory suppressions such as tactile suppression, motor control loss, auditory suppression and acuity suppression. Based on a large amount of experience reports, it appears to be considerably more likely to induce mania, delusions, and psychosis than other dissociatives (possibly due to its unusually high potency, compulsivity and erratic dose response).

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

Physical effects

Disconnective effects

Auditory effects

Transpersonal effects

Cognitive effects

Visual effects

Experience reports

Anecdotal reports which describe the effects of this compound within our experience index include:

Additional experience reports can be found here:

Toxicity and harm potential

Further information: Research chemicals § Toxicity and harm potential

The toxicity and long-term health effects of recreational 3-MeO-PCP use has not been studied in any scientific context and the exact toxic dosage is unknown. This is because 3-MeO-PCP has very short history of human usage.

There is one death involving this substance recorded in the medical literature. In this case, the invidual's cause of death was determined to be from a combination of 3-MeO-PCP, amphetamine, and diphenhydramine.[11]

Tolerance and addiction potential

The chronic use of 3-MeO-PCP can be considered highly addictive with a high potential for adverse side effects such as psychosis. In comparison to other dissociatives, 3-MeO-PCP has been reported to be more addictive than MXE, diphenidine, ephenidine, DCK, and ketamine. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage. There have been multiple reports across the internet of people becoming seriously addicted daily users of this substance so serious precautions and considerations should be taken before trying this substance.

Tolerance to many of the effects of 3-MeO-PCP develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about 3 - 7 days for the tolerance to be reduced to half and 1 - 2 weeks to be back at baseline (in the absence of further consumption). 3-MeO-PCP presents cross-tolerance with [[Cross-tolerance::all dissociatives]], meaning that after the consumption of 3-MeO-PCP, all dissociatives will have a reduced effect.

Psychosis

3-MeO-PCP has been reported to cause psychosis, delusions, and mania at a significantly higher rate than other dissociatives such as ketamine, diphenidine, or MXE. There are a large number of experience reports online which describe states of "psychotic delirium, amnesia, mania, and other serious consequences" after abusing the drug.[12][13][14] In some cases, it has resulted in hospitalization and occasionally has taken up to a week or more to resolve.[15][16][17][18][19]

It is strongly recommended that one exercise extreme caution and harm reduction practices when using this substance.

  • Users should avoid taking the drug multiple days in a row or becoming dependent/addicted to it as this seems to be the main common factor in the observed incidences of severe adverse effects.
  • The recommended dosage range should not be exceeded as high doses can trigger these effects as well.
  • Users should start with extremely low doses and work their way up as slowly as possible. Volumetric liquid dosing should preferably be used due to the drug's potency; most standard milligram scales cannot accurately weigh out doses below 10-15mg.[20]
  • Compulsive redosing before one has fully sobered up is not recommended and can result in too high of a dose.

Due to the risk of psychosis, it is not recommended to combine this drug with other substances, especially stimulants, psychedelics, or other dissociatives like MXE. Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

It is strongly recommended that one use harm reduction practices, such as volumetric dosing, when using this substance to ensure the accurate administration of the intended dose.

Urinary tract effects

In terms of its long-term health effects when used repeatedly and excessively for extended periods of time, 3-MeO-PCP seems to exhibit almost identical bladder and urinary tract problems to those found within ketamine, but to a lesser extent. This is possibly because 3-MeO-PCP is far more potent than ketamine so significantly less of drug needs to be consumed. Symptoms of ketamine-induced cystitis can become extremely serious and can be described as:

  • Urinary frequency - Urinary frequency is the need to empty the bladder every few minutes.
  • Urinary urgency - This can be described as a sudden, compelling need to urinate.
  • Urinary pressure - This is experienced as a constant sensation of fullness in the bladder that is unrelieved by urination.
  • Pelvic and bladder pain - Pain can develop suddenly and severely, particularly as the bladder fills with urine.
  • Hematuria - Hematuria is visible blood in the urine.
  • Incontinence - This is the leakage of urine.

All of these, however, can be avoided by refraining from using 3-MeO-PCP regularly (on a daily or weekly basis) and manually limiting one's usage of the substance.

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

Legality

This legality section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

  • Germany - On November 21, 2015, 3-MeO-PCP was added to "Anlage II" of the controlled substance act ("BtMG"), making it illegal to produce, sell or possess.[21]
  • Sweden - Sweden's public health agency suggested classifying 3-MeO-PCP as a hazardous substance on November 10, 2014.[22]
  • United Kingdom - 3-MeO-PCP is a class B drug in the UK and is illegal to possess, produce, supply, or import. As a derivative of 1-Phenylcyclohexylamine where the amine has been replaced with a 1-piperidyl group, further substituted in the phenyl ring with an alkoxy substituent, it is covered by the arylcyclohexylamine generic clause added to the Misuse of Drugs Act by S.I. 2013/239, which came into effect on the 26th February 2013.[23]

See also

Literature

  • Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620

References

  1. ↑ The Big & Dandy 3-MeO-PCP Thread - Part 2 (Bluelight) | http://www.bluelight.org/vb/threads/697059-The-Big-amp-Dandy-3-MeO-PCP-Thread-Part-2
  2. ↑ The Big & Dandy 3-MeO-PCP Thread - Mad Manic Meo 3nity | http://www.bluelight.org/vb/threads/760934-The-Big-amp-Dandy-3-MeO-PCP-Thread-Mad-Manic-Meo-3nity
  3. ↑ The Big & Dandy 3-MeO-PCP Thread - Part 1 (Bluelight) | http://www.bluelight.org/vb/threads/454099-The-Big-amp-Dandy-3-MeO-PCP-Thread-%28Part-1%29
  4. ↑ 4.0 4.1 4.2 3-MeO-PCP Psychosis (PsychonautWiki) | https://psychonautwiki.org/wiki/3-MeO-PCP#Toxicity_and_harm_potential
  5. ↑ 5.0 5.1 Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620
  6. ↑ 3-MeO-PCE Experience Report
  7. ↑ Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620
  8. ↑ Advisory Council on the Misuse of Drugs (ACMD) Methoxetamine report, 2012 | https://www.gov.uk/government/publications/advisory-council-on-the-misuse-of-drugs-acmd-methoxetamine-report-2012
  9. ↑ Interview with a ketamine chemist: or to be more precise, an arylcyclohexylamine chemist | http://www.vice.com/read/interview-with-ketamine-chemist-704-v18n2
  10. ↑ The Ketamine Analogue Methoxetamine and 3- and 4-Methoxy Analogues of Phencyclidine Are High Affinity and Selective Ligands for the Glutamate NMDA Receptor | http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0059334
  11. ↑ Bakota, E., Arndt, C., Romoser, A. A., & Wilson, S. K. (2016). Fatal Intoxication Involving 3-MeO-PCP: A Case Report and Validated Method. Journal of Analytical Toxicology, 40(7), 504–510. http://doi.org/10.1093/jat/bkw056
  12. ↑ 12.0 12.1 12.2 The Big & Dandy 3-MeO-PCP Thread - Part 2 (Bluelight) | http://www.bluelight.org/vb/threads/697059-The-Big-amp-Dandy-3-MeO-PCP-Thread-Part-2
  13. ↑ 13.0 13.1 13.2 The Big & Dandy 3-MeO-PCP Thread - Mad Manic Meo 3nity | http://www.bluelight.org/vb/threads/760934-The-Big-amp-Dandy-3-MeO-PCP-Thread-Mad-Manic-Meo-3nity
  14. ↑ 14.0 14.1 14.2 The Big & Dandy 3-MeO-PCP Thread - Part 1 (Bluelight) | http://www.bluelight.org/vb/threads/454099-The-Big-amp-Dandy-3-MeO-PCP-Thread-%28Part-1%29
  15. ↑ Phencyclidine analog use in Sweden--intoxication cases involving 3-MeO-PCP and 4-MeO-PCP from the STRIDA project. (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/26295489
  16. ↑ The Big & Dandy 3-MeO-PCP Thread - Part 2 | Page 18 | 10-08-2014 09:10 | Post #448 by Sekio (Administrator) | http://www.bluelight.org/vb/threads/697059-The-Big-amp-Dandy-3-MeO-PCP-Thread-Part-2?p=12523821&viewfull=1#post12523821
  17. ↑ The Big & Dandy 3-MeO-PCP Thread - Part 2 | Page 20 | 30-08-2014 14:08 | Post #481 by Chocodoobie | http://www.bluelight.org/vb/threads/697059-The-Big-amp-Dandy-3-MeO-PCP-Thread-Part-2?p=12559322&viewfull=1#post12559322
  18. ↑ The Big & Dandy 3-MeO-PCP Thread - Part 3 | Page 1 | 23-06-2015 11:53 | Post #5 by Confield | http://www.bluelight.org/vb/threads/760934-The-Big-amp-Dandy-3-MeO-PCP-Thread-Mad-Manic-Meo-3nity?p=13108675&viewfull=1#post13108675
  19. ↑ https://www.erowid.org/experiences/exp.php?ID=103972 | NumbnDumb. "So Strong I'm Shocked: An Experience with 3-MeO-PCP (ID 103972)". Erowid.org. Jan 24, 2016. erowid.org/exp/103972
  20. ↑ 3-MeO-PCP (Tripsit) | https://wiki.tripsit.me/wiki/3-MeO-PCP
  21. ↑ 30. BtMÄndVO in Kraft getreten | http://blog.beck.de/2015/11/23/30-btm-ndvo-in-kraft-getreten-6-neue-stoffe-wurden-ins-btmg-aufgenommen-0
  22. ↑ Cannabinoider föreslås bli klassade som hälsofarlig vara | http://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2014/november/cannabinoider-foreslas-bli-klassade-som-halsofarlig-vara/
  23. ↑ The Misuse of Drugs Act 1971 (Amendment) Order 2013 (Legislation.gov.uk) | http://www.legislation.gov.uk/uksi/2013/239/introduction/made
Retrieved from "http://psy.st/w/index.php?title=3-MeO-PCP&oldid=89685"